-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-520165-32-00
5
2025-11-04
BP-I mania or mania with mixed features
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-519270-40-00
5
2025-10-30
Major Depressive Disorder
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
-
2025-520541-72-00
5
2025-10-22
Major Depressive Disorder
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2023-509111-89-00
5
2025-10-15
Systemic mastocytosis with a slow course and involvement of the skin
-
2024-516234-35-00
9
2025-10-15
Relapsed or Refractory B-Cell Malignancies
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2024-520333-68-00
5
2025-09-26
Major Depressive Disorder
-
2024-519418-29-00
5
2025-09-19
Major Depressive Disorder
-
2024-513171-41-00
5
2025-09-11
Vitiligo
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-518325-15-00
5
2025-09-08
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)